1-4 of 4
Sheldon Milstien
Close
Sort by
Journal Articles

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia

Steven W. Paugh, Barbara S. Paugh, Mohamed Rahmani, Dmitri Kapitonov, Jorge A. Almenara, Tomasz Kordula, Sheldon Milstien, Jeffrey K. Adams, Robert E. Zipkin, Steven Grant, Sarah Spiegel
Journal: Blood
Blood (2008) 112 (4): 1382–1391.
https://doi.org/10.1182/blood-2008-02-138958
Published: 2008
Journal Articles

Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions

Carole A. Oskeritzian, Sergio E. Alvarez, Nitai C. Hait, Megan M. Price, Sheldon Milstien, Sarah Spiegel
Journal: Blood
Blood (2008) 111 (8): 4193–4200.
https://doi.org/10.1182/blood-2007-09-115451
Published: 2008
Journal Articles

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

Shawn G. Payne, Carole A. Oskeritzian, Rachael Griffiths, Preeti Subramanian, Suzanne E. Barbour, Charles E. Chalfant, Sheldon Milstien, Sarah Spiegel
Journal: Blood
Blood (2006) 109 (3): 1077–1085.
https://doi.org/10.1182/blood-2006-03-011437
Published: 2006
Journal Articles

Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors

Puneet S. Jolly, Meryem Bektas, Kenneth R. Watterson, Heidi Sankala, Shawn G. Payne, Sheldon Milstien, Sarah Spiegel
Journal: Blood
Blood (2005) 105 (12): 4736–4742.
https://doi.org/10.1182/blood-2004-12-4686
Published: 2005